Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands.
Leuk Res. 2013 Aug;37(8):877-82. doi: 10.1016/j.leukres.2013.03.022. Epub 2013 Apr 28.
The efficacy of azacitidine has been demonstrated in acute myeloid leukemia (AML) patients with 20-30% bone marrow (BM) blasts, but limited data is available on patients with ≥30% blasts. We analyzed 55 newly diagnosed AML patients, treated with azacitidine. The overall response rate was 42%. Median overall survival (OS) was 12.3 months. We confirmed poor-risk cytogenetics, therapy-related AML, performance score ≥2, and white blood cell count ≥15×10(9)/L as independent adverse predictors for OS. The BM blast percentage, however, had no impact on OS (P=0.55). In conclusion, administration of azacitidine is effective in AML patients with 20-30% and >30% BM blasts.
阿扎胞苷在骨髓（BM）中 blast 占比 20-30%的急性髓系白血病（AML）患者中已被证实有效，但对于 blast 占比≥30%的患者，相关数据有限。我们分析了 55 例新诊断的 AML 患者，这些患者均接受了阿扎胞苷治疗。总的缓解率为 42%。中位总生存期（OS）为 12.3 个月。我们确认不良预后核型、治疗相关 AML、表现评分为≥2 分以及白细胞计数≥15×10(9)/L 是 OS 的独立不良预测因子。然而，BM blast 百分比对 OS 没有影响（P=0.55）。总之，阿扎胞苷在骨髓中 blast 占比 20-30%和>30%的 AML 患者中均有效。
